CORONA Q2 : CONS NET PROFIT UP 15.3% AT RS 60.3 CR (YOY)

• Revenue up 22.2% at Rs 441.2 Cr (YoY); H1 revenue up 22% at Rs 863.6 Cr. • Ebitda up 22.3% at Rs 96 Cr (YoY); margins 21.7% vs 21.7% (YoY), H1 21.9% vs 20.9%. • PAT margin 13.7% vs 14.5% (YoY) on higher depreciation and amortisation from newly commissioned facilities. • Chronic plus semi-chronic contribution 71.2% vs 67.7% (YoY); four brands above Rs 100 Cr annual sales. Received ANVISA GMP certification for Bhayla, Ahmedabad facility covering OSD and women's hormone lines.

CORONA Remedies Limited

Open attachment

← Back to feed